Rucaparib blocks SARS-CoV-2 virus binding to cells and interleukin-6 release in a model of COVID-19
Papp, H.; Bovari-Biri, J.; Banfai-Biri, K.; Juhasz, P.; Mahdi, M.; Russo, L. C.; Bajusz, D.; Sipos, A.; Petri, L.; Kemeny, A.; Madai, M.; Kuczmog, A.; Batta, G.; Mozner, O.; Vasko, D.; Hirsch, E.; Bohus, P.; Mehes, G.; Tozser, J.; Curtin, N. J.; Helyes, Z.; Toth, A.; Hoch, N.; Jakab, F.; Keseru, G.; Pongracz, J. E.; Bai, P.
Show abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 virus, is a major global health challenge, as there is no efficient treatment for the moderate to severe disease. ADP-ribosylation events are involved in regulating the life cycle of coronaviruses and the inflammatory reactions of the host, hence we assessed the repurposing of registered PARP inhibitors for the treatment of COVID-19. We detected high levels of oxidative stress and strong PARylation in all cell types in the lungs of COVID-19 patients. Interestingly, rucaparib, unlike other PARP inhibitors, reduced SARS-CoV-2 infection rate through binding to the conserved 493-498 amino acid region located in the spike-ACE2 interface in the spike protein and prevented viruses from binding to ACE2. In addition, the spike protein-induced overexpression of IL-6, a key cytokine in COVID-19, was inhibited by rucaparib at pharmacologically relevant concentrations. These findings build a case for repurposing rucaparib for treating COVID-19 disease.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dysregulation in mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells 91%
- SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts. 90%
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 90%
Similar papers in this journal
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 93%
- A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2 93%
- Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro 92%
Similar papers in this journal
- SARS-CoV-2 fears green: the chlorophyll catabolite Pheophorbide a is a potent antiviral 93%
- Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo 92%
- Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.